BRCA1 and prostate carcinoma: The efficacy of PARP inhibitors as a therapeutic option in prostate cancer is achieved through a “synthetic lethality” process with a simultaneous loss of double-stranded DNA repair function by homologous recombination (HR), in which BRCA1/BRCA2 proteins play an essential role [32].